السوق العالمية لخلايا الدبقيات القليلة التغصن - اتجاهات الصناعة والتوقعات حتى عام 2028

تحليل السوق والرؤى : سوق الخلايا الدبقية القليلة التغصن العالمية

من المتوقع أن يحقق سوق أوليغوديندروجليوما نموًا في السوق في الفترة المتوقعة من 2021 إلى 2028. تحلل شركة Data Bridge Market Research السوق لتأخذ في الاعتبار النمو بمعدل نمو سنوي مركب قدره 4.30% في الفترة المتوقعة المذكورة أعلاه.

الورم الدبقي القليل التغصن هو ورم يصيب الجهاز العصبي المركزي. يتطور في المخ أو النخاع الشوكي. ويحدث بسبب الخلايا الدبقية القليلة التغصن. الخلايا الدبقية القليلة التغصن هي الخلايا الموجودة في المخ والحبل الشوكي والتي تنتج مادة تساعد في حماية الخلايا العصبية. أعراض هذه الحالة هي الصداع والضعف ومشاكل في التفكير والذاكرة والخدر والنوبات ومشاكل في التوازن والحركة.  

إن ارتفاع معدل انتشار السرطان هو المحرك الرئيسي الذي سيؤثر على نمو السوق. علاوة على ذلك، فإن الإنفاق المتزايد على الرعاية الصحية والتقدم التكنولوجي والتمويل الحكومي المتزايد والمبادرات المتزايدة من قبل الحكومة والمنظمات الخاصة لنشر الوعي حول المرض وعلاجاته المتاحة هي العوامل التي ستوسع سوق الخلايا الدبقية القليلة التغصن.

ستوفر الزيادة في أنشطة البحث والتطوير والتجارب السريرية الجارية فرصًا مفيدة لسوق الخلايا القليلة التغصن في الفترة المتوقعة 2021-2028.

ومع ذلك، فإن التكلفة العالية للعلاج والآثار الجانبية المرتبطة بالعلاجات مثل العلاج الكيميائي هي العوامل التي ستعيق نمو السوق، كما أن الافتقار إلى الوعي سيشكل تحديًا لسوق الأورام الدبقية القليلة التغصن في فترة التنبؤ المذكورة أعلاه.

This oligodendroglioma market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the oligodendroglioma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Oligodendroglioma Market Scope and Market Size

The oligodendroglioma market is segmented on the basis of grade, drug type, treatment, diagnosis, dosage, route of administration, symptoms, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of grade, the oligodendroglioma market is segmented into grade 2 and grade 3.
• On the basis of drug type, the oligodendroglioma market is segmented into bevacizumab, alisertib, dasatinib, DCVax-L, CDX-1401, IMA-950 and others.
• On the basis of treatment, the oligodendroglioma market is segmented into surgery, chemotherapy, radiation therapy, palliative care and others.
• On the basis of diagnosis, the oligodendroglioma market is segmented into blood tests, CT scan, MRI, biopsy and others.
• On the basis of dosage, the oligodendroglioma market is segmented into tablet, injection and others.
• On the basis of route of administration, the oligodendroglioma market is segmented into oral, intravenous and others.
• On the basis of symptoms, the oligodendroglioma market is segmented into headaches, weakness, problems with thinking and memory, numbness, seizures, problems with balance and movement, and others.
• On the basis of end-users, the oligodendroglioma market is segmented into clinic, hospital and others.

The oligodendroglioma market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Oligodendroglioma Market Country Level Analysis

Oligodendroglioma market is analyzed and market size information is provided by the country, grade, drug type, treatment, diagnosis, dosage, route of administration, symptoms, end-users and distribution channel as referenced above.

The countries covered in the oligodendroglioma market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the oligodendroglioma market due to the presence of major key players, growing investment for R&D activities, high disposable income, high healthcare expenditure and well-developed healthcare sector in this region. Asia-Pacific is expected to grow during the forecast period of 2021-2028 due to the increasing research and development activities, rising investment in the healthcare sector and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Oligodendroglioma market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Oligodendroglioma Market Share Analysis

Oligodendroglioma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to oligodendroglioma market research.

اللاعبون الرئيسيون الذين تم تغطيتهم في تقرير سوق أورام الخلايا الدبقية القليلة التغصن هم Angiochem Inc. وBristol-Myers Squibb Company وBoehringer Ingelheim International GmbH وJazz Pharmaceuticals, Inc. وLilly وCelldex Therapeutics وF. Hoffmann-La Roche Ltd. وImmatics NV وPfizer Inc. وNovartis AG وIpsen Pharma وLeadiant Biosciences, Inc. وTakeda Pharmaceutical Company Limited وNorthwest Biotherapeutics, Inc. وTocagen Inc.، من بين لاعبين محليين وعالميين آخرين. تتوفر بيانات حصة السوق لكل من العالم وأمريكا الشمالية وأوروبا وآسيا والمحيط الهادئ (APAC) والشرق الأوسط وأفريقيا (MEA) وأمريكا الجنوبية بشكل منفصل. يفهم محللو DBMR نقاط القوة التنافسية ويقدمون تحليلًا تنافسيًا لكل منافس على حدة.

SKU-66772